Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07591740 · ClinicalTrials.gov registry record
Xpert Hemorrhagic Fever on Edge X in Trained and Untrained Users
A clinical trial, sponsored by Cepheid.
- Completed
- Registry status
- 725
- Enrollment target
NCT07591740: Completed study, sponsored by Cepheid.
NCT07591740 is a clinical trial that has completed, run by Cepheid. The registered enrollment target is 725 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07591740 has completed, sponsored by Cepheid.
- COMPLETED
- Registry status
- 725 participants
- Enrollment target
Study Summary
A multi-site observation study that was conducted in the United States at 3 CLIA Waived sites with Untrained Users testing on Xpert Hemorrhagic fever tests on Edge X instruments
Primary Outcome
Evaluating the PPA and NPA of Xpert compared to expected status of specimens
Interventions
- DIAGNOSTIC_TEST Xpert Hemorrhagic Fever test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 725 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2026-03-13 |
What the finished NCT07591740 record still lists
NCT07591740 is an observational study that tracks outcomes without assigning an intervention. The registered 725 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Xpert Hemorrhagic Fever test is the first listed.
NCT07591740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07591740 about?
NCT07591740 is a clinical study titled "Xpert Hemorrhagic Fever on Edge X in Trained and Untrained Users". A multi-site observation study that was conducted in the United States at 3 CLIA Waived sites with Untrained Users testing on Xpert Hemorrhagic fever tests on Edge X instruments
What is the current status of trial NCT07591740?
This trial is currently completed. The enrollment target is 725 participants. The study started on 2024-10-21. Estimated completion is 2026-03-13.
What interventions are being tested in trial NCT07591740?
The interventions under investigation include: Xpert Hemorrhagic Fever test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07591740?
This trial is sponsored by Cepheid, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI